MCK Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Scale And Revenue GrowthMcKesson’s enormous distribution scale and sustained revenue expansion support customer reach, purchasing leverage and network efficiency. Continued volume growth across pharmaceuticals and healthcare services provides a durable foundation for earnings over the next several quarters.
Strong Cash GenerationRobust operating and free cash flow indicate that reported earnings convert effectively into liquidity. This supports investment, debt servicing, shareholder returns and strategic initiatives, although historical free-cash-flow volatility means conversion may remain uneven between quarters.
Specialty And Core Segment MomentumFast growth in Oncology & Multispecialty, alongside positive pharmaceutical and technology-services outlooks, improves McKesson’s mix beyond traditional distribution. Specialty therapies and authorization services can deepen customer relationships and support higher-value expansion.
Bears Say
Persistently Negative Stockholders’ EquityNegative equity reduces balance-sheet flexibility and makes leverage and return metrics harder to interpret. It leaves less accounting cushion in a downside scenario, particularly if operating conditions weaken or separation-related obligations increase.
Thin And Compressing Distribution MarginsVery thin margins leave profitability sensitive to purchasing terms, customer pricing, product mix and reimbursement changes. The multi-year gross-margin decline suggests limited room to absorb competitive pressure, branded pricing changes or unexpected operating costs.
MedSurg And Policy ExposureThe MedSurg decline highlights execution and mix pressure during the portfolio separation. At the same time, drug-pricing and reimbursement policy changes could alter volumes, revenue and economics, creating persistent uncertainty across the distribution model.
McKesson News
MCK FAQ
What was Mckesson Corp.’s price range in the past 12 months?
Currently, no data Available
What is Mckesson Corp.’s market cap?
Mckesson Corp.’s market cap is CHF81.68B.
When is Mckesson Corp.’s upcoming earnings report date?
Mckesson Corp.’s upcoming earnings report date is Nov 03, 2026 which is in 69 days.
How were Mckesson Corp.’s earnings last quarter?
Mckesson Corp. released its earnings results on Aug 05, 2026. The company reported $7.977 earnings per share for the quarter, beating the consensus estimate of $7.68 by $0.296.
Is Mckesson Corp. overvalued?
According to Wall Street analysts Mckesson Corp.’s price is currently Undervalued.
Does Mckesson Corp. pay dividends?
Mckesson Corp. does not currently pay dividends.
What is Mckesson Corp.’s EPS estimate?
Mckesson Corp.’s EPS estimate is 8.61.
How many shares outstanding does Mckesson Corp. have?
Currently, no data Available
What happened to Mckesson Corp.’s price movement after its last earnings report?
Mckesson Corp. reported an EPS of $7.977 in its last earnings report, beating expectations of $7.68. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Mckesson Corp.?
Currently, no hedge funds are holding shares in CH:MCK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
McKesson Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF793.46 (― Upside)
CHF793.46 (― Upside)
Blogger Sentiment
Bullish
CH:MCK Sentiment 67%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth CHF218.1K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
19.90%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
8.63%
Trailing 12-Months
Company Description
Mckesson Corp.
McKesson Corporation is a prominent global provider of healthcare services, operating extensively in both the United States and international markets. Its diverse operations are strategically organized into four key business segments. The U.S. Pharmaceutical division plays a crucial role in the distribution of a comprehensive array of pharmaceutical products, encompassing branded, generic, specialty, biosimilar, and over-the-counter medications, alongside other health-related merchandise. This segment also delivers specialized support to community-based oncology and other specialty medical practices through practice management tools, technology solutions, clinical guidance, and broader business services. Furthermore, it assists pharmacies with consulting, outsourcing, and technology services, while also furnishing financial, operational, and clinical software solutions. Internationally, the company's dedicated segment provides distribution and support services to wholesale, institutional, and retail clients across 13 European nations and Canada. The Medical-Surgical Solutions unit is focused on supplying healthcare providers with essential medical-surgical products, sophisticated logistics management, and a variety of associated services. Finally, the Prescription Technology Solutions (RxTS) segment is designed to address complex medication challenges for patients. It collaborates with biopharmaceutical companies and life sciences partners to improve patient journeys, leveraging innovative solutions for medication access and adherence by connecting pharmacies, healthcare providers, payers, and biopharma entities. This segment further offers third-party logistics and wholesale distribution assistance. Founded in 1833, McKesson Corporation maintains its corporate headquarters in Irving, Texas.
MCK Company Deck
MCK Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated strong operational momentum: double-digit EPS growth, an 8% revenue increase to $105.4B, broad-based segment strength (notably Oncology & Multispecialty and North American Pharmaceuticals), improved gross profit and operating leverage, a raised full-year EPS guide, active capital returns (large buyback and dividend increase), and continued strategic progress on the MedSurg separation and tech/AI initiatives. Lowlights included a quarterly negative free cash flow readout (seasonal but improved vs prior year), a 20% decline in MedSurg operating profit, financing-related interest expense and GAAP remeasurement charges, and macro/regulatory uncertainties (WAC reductions, branded-to-generic conversions, 340B/IRA policy risks). Overall, the positive operational and financial beats and raised guidance materially outweigh the noted one-offs, financing costs, and policy risks.View all CH:MCK earnings summariesMCK Revenue Breakdown
83.45% North American Pharmaceutical
12.00% Oncology & Multispecialty
1.44% Prescription Technology Solutions
2.85% Medical-Surgical Solutions
0.26% Other
MCK Stock 12 Month Forecast
Average Price Target
―Cencora
―
Cardinal Health
―
Henry Schein
―
Prestige Consumer Healthcare
―
Guardian Pharmacy Services, Inc. Class A
―